Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Q1 2025 Management View CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product launches such as WINREVAIR and CAPVAXIVE. Revenue for ...

Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the approval covers the 21-valent ...

Despite the positive drug trial outcomes and regulatory progress with CAPVAXIVE and subcutaneous pembrolizumab, overall market conditions appear to have overshadowed these achievements ...

The EC’s decision enables the marketing of CAPVAXIVE across the 27 European Union member states, as well as in Iceland, Liechtenstein, and Norway. The approval, which follows a positive ...

CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product launches such as WINREVAIR and CAPVAXIVE. Revenue for Q1 2025 reached $15 ...